A Double‐Blind Comparison of Haloperidol Oral Concentrate, Haloperidol Solutabs and Placebo in the Treatment of Chronic Schizophrenia

Ota, Kay Y.; Kurland, Albert A.

doi:10.1002/j.1552-4604.1973.tb00259.x

Cited by 4 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After removing duplicates and examining titles and abstracts, we selected 514 records for full‐text assessment. Of these, 100 primary studies were eligible for inclusion (corresponding to 99 full‐text articles 57‐155 , as one paper reported on two trials). Of these, 92 studies, including 22,645 participants, provided data for ≥1 outcome of interest (see Figure 1).…”

Section: Resultsmentioning

confidence: 99%

Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants

et al. 2022

View full text Add to dashboard Cite

According to current evidence and guidelines, continued antipsychotic treatment is key for preventing relapse in people with schizophrenia‐spectrum disorders, but evidence‐based recommendations for the choice of the individual antipsychotic for maintenance treatment are lacking. Although oral antipsychotics are often prescribed first line for practical reasons, long‐acting injectable antipsychotics (LAIs) are a valuable resource to tackle adherence issues since the earliest phase of disease. Medline, EMBASE, PsycINFO, CENTRAL and CINAHL databases and online registers were searched to identify randomized controlled trials comparing LAIs or oral antipsychotics head‐to‐head or against placebo, published until June 2021. Relative risks and standardized mean differences were pooled using random‐effects pairwise and network meta‐analysis. The primary outcomes were relapse and dropout due to adverse events. We used the Cochrane Risk of Bias tool to assess study quality, and the CINeMA approach to assess the confidence of pooled estimates. Of 100 eligible trials, 92 (N=22,645) provided usable data for meta‐analyses. Regarding relapse prevention, the vast majority of the 31 included treatments outperformed placebo. Compared to placebo, “high” confidence in the results was found for (in descending order of effect magnitude) amisulpride‐oral (OS), olanzapine‐OS, aripiprazole‐LAI, olanzapine‐LAI, aripiprazole‐OS, paliperidone‐OS, and ziprasidone‐OS. “Moderate” confidence in the results was found for paliperidone‐LAI 1‐monthly, iloperidone‐OS, fluphenazine‐OS, brexpiprazole‐OS, paliperidone‐LAI 1‐monthly, asenapine‐OS, haloperidol‐OS, quetiapine‐OS, cariprazine‐OS, and lurasidone‐OS. Regarding tolerability, none of the antipsychotics was significantly worse than placebo, but confidence was poor, with only aripiprazole (both LAI and OS) showing “moderate” confidence levels. Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for the maintenance treatment of schizophrenia‐spectrum disorders, considering that both LAI and oral formulations of these antipsychotics are among the best‐performing treatments and have the highest confidence of evidence for relapse prevention. This finding is of particular relevance for low‐ and middle‐income countries and constrained‐resource settings, where few medications may be selected. Results from this network meta‐analysis can inform clinical guidelines and national and international drug regulation policies.

show abstract

Section: Resultsmentioning

confidence: 99%

Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants

et al. 2022

View full text Add to dashboard Cite

show abstract

Maintenance treatment with antipsychotic drugs for schizophrenia

Ceraso

Lin

Schneider‐Thoma

et al. 2020

Cochrane Database of Systematic Reviews

101

View full text Add to dashboard Cite

show abstract

Haloperidol discontinuation for people with schizophrenia

Essali

Turkmani

Aboudamaah

et al. 2019

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Schizophrenia is a disabling serious mental illness that can be chronic. Haloperidol, one of the first generation of antipsychotic drugs, is effective in the treatment of schizophrenia but can have adverse side effects. The effects of stopping haloperidol in people with schizophrenia who are stable on their prescription are not well researched in the context of systematic reviews. Objectives To review the effects of haloperidol discontinuation in people with schizophrenia who are stable on haloperidol.

show abstract

A Double‐Blind Comparison of Haloperidol Oral Concentrate, Haloperidol Solutabs and Placebo in the Treatment of Chronic Schizophrenia

Cited by 4 publications

References 4 publications

Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants

Oral and long‐acting antipsychotics for relapse prevention in schizophrenia‐spectrum disorders: a network meta‐analysis of 92 randomized trials including 22,645 participants

Maintenance treatment with antipsychotic drugs for schizophrenia

Haloperidol discontinuation for people with schizophrenia

Contact Info

Product

Resources

About